STAT

DECEMBER 19, 2024

generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found. Most of the formularies run by some of the largest health plans in the U.S.

Department of Veterans Affairs 285

Department of Veterans Affairs Diabetes Drug Pricing 285

STAT

FEBRUARY 23, 2024

In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a contentious state law designed to bring more transparency to prescription drug pricing. District Court judge sided with an industry trade group that had argued a portion of the law was unconstitutional.

Drug Pricing 283

Drug Pricing 283

STAT

NOVEMBER 15, 2023

The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers: One that would replace PBM fees that are tied to a percentage of drug prices with flat fees Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments A third that would require PBMs to report (..)

Drug Pricing 312

Drug Pricing Biosimilars 312

STAT

MARCH 17, 2025

The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.

Biosimilars 215

Biosimilars Hospitals Pharmaceutical Companies Pharmaceutical Companies 215

STAT

MAY 6, 2024

Federal Trade Commission wants more information on a $16.5 million deal in which Novo Nordisk’s parent company would purchase Catalent, a contract drug manufacturer, weeks after an application to the regulator was refiled for approval of the deal, Reuters notes.

Drug Pricing 264

Drug Pricing 264

STAT

MAY 14, 2024

We want to know how to make this newsletter more informative and helpful for you.   Sign up  to get our biotech newsletter in your inbox. Good morning. I’m making another plea to please fill out our  brief survey ! Read the rest…

Drug Pricing 290

Drug Pricing Drug Development 290

STAT

SEPTEMBER 18, 2024

Once the Food and Drug Administration approves a medicine, this information is filed in the Orange Book , a key registry that plays a crucial, behind-the-scenes role in sorting out the competitive landscape in the pharmaceutical industry.

Generic Medicine 356

Generic Medicine Drug Pricing 356

STAT

JULY 10, 2024

The FTC said its findings were interim, though, because some companies did not provide all of the requested information and threatened further action. billion prescriptions that were dispensed by U.S. pharmacies in 2023.

Drug Pricing 363

Drug Pricing Diabetes 363

STAT

JULY 23, 2024

The committee found evidence of PBMs sharing patient information among affiliated companies for the specific and anticompetitive purpose of steering patients to pharmacies a PBM owns.

Packaging 343

Packaging Drug Pricing 343

Pharmaceutical Technology

DECEMBER 9, 2022

There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drug pricing reforms and remote medicine. The post The Brazilian pharma market: Key information and what may change appeared first on Pharmaceutical Technology.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

STAT

JUNE 16, 2023

trade group has rebuked Leo Pharma for a “serious and extremely concerning” violation of voluntary codes after learning a company manager coerced staff into gaining competitive information. The Leo manager wanted the pricing information in order to bolster its submission to the U.K.’s

Drug Pricing 246

Drug Pricing 246

STAT

MAY 4, 2023

but its contributions to drug development are not well understood or recognized by most Americans. And a new analysis finds a key reason may be most institutions and researchers that receive NIH support fail to fully or correctly disclose this information when applying for patents. Government Accountability Office.

Drug Development 258

Drug Development Drug Pricing 258

STAT

NOVEMBER 11, 2024

 The pharmaceutical industry is poised for an opportunity to tweak parts of the Medicare drug pricing negotiation law, after Republicans took control of the White House and Senate. DMFs are submitted to the FDA by companies supplying drug ingredients to another company and are confidential and stripped of proprietary information.

Drug Pricing 257

Drug Pricing 257

STAT

SEPTEMBER 15, 2023

The regulator did not provide any details other than to say it has information suggesting a “reasonable suspicion” the company may also have engaged in “exclusionary practices.” ” We asked J&J for comment and will update you accordingly.

Drug Pricing 304

Drug Pricing 304

STAT

JUNE 14, 2024

The vote means the board will decide in a follow-up meeting whether to pursue an upper payment limit for the drug, which an affordability review found cost an average of roughly $47,000 per patient in 2022. Yet two years ago, Cosentyx was used by 1,128 residents compared to all of the available alternatives in the same class of medicines.

Drug Pricing 290

Drug Pricing 290

BioPharma Dive

MARCH 28, 2023

The state’s Attorney General David Yost called pharmacy benefit managers “modern gangsters,” claiming in a suit filed Monday they shared pricing information and drove up drug prices.

Drug Pricing 109

Drug Pricing 109

STAT

MAY 18, 2023

Supreme Court upheld a lower court ruling that Amgen failed to disclose sufficient information about patent claims for a best-selling drug. The case had its roots in a long-running battle between Amgen and two other drug companies — Sanofi and Regeneron Pharmaceuticals — that market a rival cholesterol treatment.

Drug Pricing 246

Drug Pricing Biosimilars 246

STAT

JANUARY 17, 2023

generally provide “fair access” to 19 treatments for a handful of serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis found. Most of the largest health plans in the U.S.

Drug Pricing 263

Drug Pricing 263

STAT

DECEMBER 14, 2024

However, the credit would only be issued after the hospital or clinic submits claims data, including the prescription order, a patient’s hospital visit, and dispensing information. Continue to STAT+ to read the full story…

Hospitals 273

Hospitals Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 273

Drug Channels

AUGUST 8, 2023

senators issued a request for information (RFI) for “input on bipartisan policy solutions that would provide stability and appropriate transparency to ensure the 340B program can continue to achieve its original intent of supporting entities serving eligible patients.” Recently, a bipartisan group of six U.S.

Drug Pricing 96

Drug Pricing Hospitals 96

STAT

SEPTEMBER 13, 2024

Food and Drug Administration to warn and potentially impose costly fines on those who post false information online about medicines, or omit important information about a drug’s safety risks.  Dick Durbin (D., and Mike Braun (R., would authorize the U.S.

Medical Records 263

Medical Records Labelling Diabetes Drug Pricing 263

STAT

SEPTEMBER 15, 2022

The Swiss Competition Commission has begun an investigation into Novartis over the possible unlawful use of a patent to block competitors for some of its medicines, the latest instance in which European authorities have probed drug companies for antitrust infractions. billion in sales in the first half of 2022.

Drug Pricing 246

Drug Pricing 246

STAT

OCTOBER 24, 2024

Notably, 60% of the reasons for shortages were unknown or manufacturers would not provide a reason, according to the University of Utah Drug Information Service, which collected the data. By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401.

Immunization 258

Immunization Immunity Drug Pricing Drug Development 258

STAT

SEPTEMBER 10, 2024

The pair envisions Highlander allowing clients to harness the data generated from real-world medical practice — particularly after medicines are approved — to inform the research and development process. Read the rest…

Drug Pricing 255

Drug Pricing Drug Development 255

Drug Patent Watch

JANUARY 7, 2025

As healthcare professionals, it’s our responsibility to educate patients about generic drugs and empower them to make informed decisions about their treatment options. Increased competition: The availability of generic alternatives helps drive down overall drug prices.

Communication 85

Communication Dosage Drug Pricing Packaging 85

Putting Patients First Blog

MAY 22, 2023

The NHC is concerned that 30 days to submit data after CMS releases the list of drugs to be negotiated is insufficient time for organizations, who do not have research and/or data analysis departments and staff, to collect information and submit data that is most beneficial to CMS.

Drug Pricing 40

Drug Pricing Drug Development 40

STAT

JUNE 13, 2023

Some want PBMs to disclose more information about their business practices. Others want to block so-called spread pricing, in which PBMs charge insurance plans far more for a drug than PBMs pay pharmacies to dispense. Health secretary Xavier Becerra testified at the hearing on his department’s priorities.

Independent Pharmacies 246

Independent Pharmacies Drug Pricing 246

Putting Patients First Blog

NOVEMBER 14, 2023

NHC Comments on Request for Information: Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program (PDF) November 13, 2023 Benjamin Stidham, Contract Specialist Centers for Medicare & Medicaid Services U.S. The right to encryption: privacy as preventing unlawful access.

Drug Pricing 40

Drug Pricing Specialty Pharmacies HIPAA Payment Processing 40

Putting Patients First Blog

APRIL 27, 2023

NHC Medicare Drug Price Negotiation Program Comments April 27, 2023 By: Allen Pinn, Coordinator, Policy April 14, the National Health Council (NHC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act.

Drug Pricing 52

Drug Pricing 52

Pharma Marketing Network

MARCH 13, 2025

However, growing concerns about drug pricing, misleading claims, and overprescription have led policymakers to consider banning pharma ads from television altogether. Google Ads and Paid Search : Patients frequently search for information about treatments and symptoms. Interactive patient quizzes helping users assess symptoms.

Drug Pricing 59

Drug Pricing Online Pharmacies Drug Development 59

Drug Channels

MAY 21, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 4, 2025

Pharmacies and Pharmacy Benefit Managers , Dr. Fein will provide invaluable insights to help you and your team stay informed about this rapidly evolving market. Register now to stay informed and ahead of the curve on the PBM industry! Or, download this spreadsheet and email your registrants information to dcisupport@hmpglobal.com.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Labelling 98

Big Molecule Watch

AUGUST 29, 2023

HHS has announced the ten drugs that will be included in the first year of the Inflation Reduction Act’s new Drug Price Negotiation Program. Of the 10 drugs, three are biologics (ENBREL, STELARA, and the FIASP and NOVOLOG products). The remainder are small-molecule drugs.

Drug Pricing 49

Drug Pricing 49

Big Molecule Watch

OCTOBER 2, 2023

Ohio, Judge Newman) issued the first substantive order addressing legal challenges to the Drug Price Negotiation Program of the Inflation Reduction Act. Today, October 2, is the statutory deadline for companies to provide certain information to CMS to facilitate the negotiation process. Becerra et al.

Drug Pricing 64

Drug Pricing Documentation 64

FDA Law Blog: Biosimilars

JUNE 16, 2023

Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.

Drug Pricing 45

Drug Pricing Biosimilars Dosage Documentation 45

Drug Channels

JULY 5, 2022

Join Dr. Fein as he helps you and your team stay on top of the latest trends, market data, and strategies for specialty drugs. He will draw from exclusive information found in DCI’s industry economic reports. WHAT YOU WILL LEARN.

Drug Pricing 98

Drug Pricing 98

Drug Channels

NOVEMBER 9, 2022

Dr. Fein will draw from exclusive information found in DCI’s industry economic reports. Fein as he helps you and your team get ready for 2023 by outlining key issues and uncertainties that will surely affect your planning. This event can be both a capstone of your annual learning and a touchpoint for the future.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 98